Full Year Trading Update

Optima Health PLC

17 April 2026

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

17 April 2026

Optima Health plc

("Optima", the "Company", and, together with its subsidiaries, the "Group")

Full Year Trading Update

Full year adjusted EBITDA expected to be c.10% ahead of market expectations

Optima Health (AIM: OPT), the UK's leading provider of technology enabled corporate health and wellbeing solutions, today announces an unaudited trading update for the year ended 31 March 2026.

Further to the previously communicated commentary on current trading announced on 31 March 2026, Optima now expects FY26 Adjusted EBITDA to be ahead of market expectations[1] by c.10%.

Optima has continued to make strong progress against its strategic objectives and medium-term targets of £200 million revenue and £40 million adjusted EBITDA. The recent acquisition of PAM, which completed on 26 March 2026, positions the enlarged Group to capitalise on the growing market opportunity, whilst benefiting from significant operational and cost synergies which will help Optima achieve its medium-term EBITDA target.

The previously disclosed procurement matter has now been settled. Other operating income of £2.3 million was recognised in H1 FY26, and a further £2.4 million has been recognised in H2 FY26.

A full trading update will be made later in Q2 2026.

Jonathan Thomas, Chief Executive Officer, said: "Optima's strong financial performance in H2, ahead of market expectations, reflects the consistent progress we have continued to make against our strategic objectives. The recent transformational acquisition of PAM has further solidified Optima's position in the attractive and growing occupational health market. We look forward to increasing our presence in our core markets, alongside seeking new opportunities, as we continue to accelerate growth."

  Enquiries

Optima Health Jonathan Thomas, CEO Heidi Giles, CFO	[phone] [e-mail]
Panmure Liberum Limited Nominated Adviser and Corporate Broker Emma Earl / Will Goode/ Mark Rogers Rupert Dearden	[phone]
Cavendish Capital Markets Joint Broker Geoff Nash/Ben Jeynes/George Lawson Julian Morse/Michael Johnson/Nigel Birks	+ 44 (0)20 7220 0500
ICR Healthcare UK Financial PR Adviser Mary-Jane Elliott / Angela Gray / Lindsey Neville	[e-mail]

About Optima Health

Optima Health is the UK's leading provider of occupational health and wellbeing services, delivering clinically led, technology-driven solutions to organisations across the public and private sectors. With a team of more than 2,000 including 1,250 clinicians, Optima Health supports millions of employees and operates from a network of more than 50 clinics nationwide.

 In addition to its core UK market, Optima Health also operates in Ireland under Optima Health Ireland, providing occupational health services to clients nationwide.

For more information visit www.optimahealth.co.uk

---

[1] FY26 adjusted EBITDA market consensus £18.1 million

 

END